BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support
BD (NYSE: BDX) has launched HemoSphere Alta™, an advanced hemodynamic monitoring platform featuring AI-driven algorithms to help clinicians manage blood pressure and flow during critical procedures. The platform introduces the first-of-its-kind Cerebral Autoregulation Index (CAI), which monitors brain blood flow stability using ForeSight IQ™ and Acumen IQ™ sensors.
The system includes the Acumen Hypotension Prediction Index (HPI)™ software, proven to reduce hypotension severity in multicenter studies. Notable features include a 15" high-resolution touchscreen, split-screen views, voice and gesture commands, and minimal pop-ups for improved user experience.
This launch represents the first major product from BD's Advanced Patient Monitoring business since its acquisition, advancing BD's position in smart, connected care technologies.
BD (NYSE: BDX) ha lanciato HemoSphere Alta™, una piattaforma avanzata di monitoraggio emodinamico che utilizza algoritmi basati sull'intelligenza artificiale per aiutare i medici a gestire pressione sanguigna e flusso durante procedure critiche. La piattaforma introduce il primo Indice di Autoregolazione Cerebrale (CAI) del suo genere, che monitora la stabilità del flusso sanguigno cerebrale grazie ai sensori ForeSight IQ™ e Acumen IQ™.
Il sistema include il software Acumen Hypotension Prediction Index (HPI)™, dimostrato efficace nel ridurre la gravità dell'ipotensione in studi multicentrici. Tra le caratteristiche principali ci sono uno schermo touch da 15" ad alta risoluzione, visualizzazioni a schermo diviso, comandi vocali e gestuali, e notifiche ridotte per migliorare l'esperienza d'uso.
Questo lancio rappresenta il primo prodotto importante del business Advanced Patient Monitoring di BD dopo l'acquisizione, rafforzando la posizione di BD nelle tecnologie di cura intelligente e connessa.
BD (NYSE: BDX) ha lanzado HemoSphere Alta™, una plataforma avanzada de monitoreo hemodinámico que utiliza algoritmos impulsados por inteligencia artificial para ayudar a los clínicos a gestionar la presión arterial y el flujo durante procedimientos críticos. La plataforma presenta el primer Índice de Autorregulación Cerebral (CAI) de su tipo, que monitorea la estabilidad del flujo sanguíneo cerebral mediante los sensores ForeSight IQ™ y Acumen IQ™.
El sistema incluye el software Acumen Hypotension Prediction Index (HPI)™, demostrado para reducir la gravedad de la hipotensión en estudios multicéntricos. Entre sus características destacadas están una pantalla táctil de alta resolución de 15", vistas en pantalla dividida, comandos de voz y gestos, y notificaciones mínimas para mejorar la experiencia del usuario.
Este lanzamiento representa el primer producto importante del negocio Advanced Patient Monitoring de BD desde su adquisición, reforzando la posición de BD en tecnologías inteligentes y conectadas para el cuidado.
BD (NYSE: BDX)는 AI 기반 알고리즘을 활용하여 임상 의사가 중대한 절차 중 혈압과 혈류를 관리할 수 있도록 돕는 첨단 혈역학 모니터링 플랫폼 HemoSphere Alta™를 출시했습니다. 이 플랫폼은 ForeSight IQ™ 및 Acumen IQ™ 센서를 사용하여 뇌 혈류 안정성을 모니터링하는 최초의 뇌 자기조절 지수(CAI)를 도입했습니다.
시스템에는 다기관 연구에서 저혈압 심각도를 줄이는 것으로 입증된 Acumen 저혈압 예측 지수(HPI)™ 소프트웨어가 포함되어 있습니다. 주요 기능으로는 15인치 고해상도 터치스크린, 분할 화면 보기, 음성 및 제스처 명령, 최소한의 팝업 알림으로 향상된 사용자 경험이 있습니다.
이번 출시는 BD가 인수한 이후 Advanced Patient Monitoring 사업부에서 선보이는 첫 주요 제품으로, BD의 스마트 연결형 케어 기술 입지를 강화합니다.
BD (NYSE : BDX) a lancé HemoSphere Alta™, une plateforme avancée de surveillance hémodynamique intégrant des algorithmes pilotés par IA pour aider les cliniciens à gérer la pression artérielle et le flux sanguin lors de procédures critiques. La plateforme introduit le premier Indice d'Autorégulation Cérébrale (CAI) de ce type, qui surveille la stabilité du flux sanguin cérébral grâce aux capteurs ForeSight IQ™ et Acumen IQ™.
Le système comprend le logiciel Acumen Hypotension Prediction Index (HPI)™, dont l'efficacité pour réduire la gravité de l'hypotension a été démontrée dans des études multicentriques. Parmi ses fonctionnalités notables figurent un écran tactile haute résolution de 15", des vues en écran partagé, des commandes vocales et gestuelles, ainsi que des notifications minimales pour une meilleure expérience utilisateur.
Ce lancement constitue le premier produit majeur de la division Advanced Patient Monitoring de BD depuis son acquisition, renforçant la position de BD dans les technologies de soins intelligents et connectés.
BD (NYSE: BDX) hat HemoSphere Alta™ eingeführt, eine fortschrittliche hämodynamische Überwachungsplattform mit KI-gesteuerten Algorithmen, die Klinikern helfen, Blutdruck und Durchfluss während kritischer Eingriffe zu steuern. Die Plattform stellt den ersten Zerebralen Autoregulationsindex (CAI) seiner Art vor, der die Stabilität des Hirnblutflusses mithilfe der Sensoren ForeSight IQ™ und Acumen IQ™ überwacht.
Das System beinhaltet die Software Acumen Hypotension Prediction Index (HPI)™, die in multizentrischen Studien nachweislich die Schwere von Hypotonie reduziert. Zu den bemerkenswerten Merkmalen zählen ein 15" hochauflösendes Touchscreen, geteilte Bildschirmansichten, Sprach- und Gestensteuerung sowie minimale Pop-ups für eine verbesserte Benutzererfahrung.
Dieser Launch stellt das erste bedeutende Produkt der Advanced Patient Monitoring-Sparte von BD seit der Übernahme dar und stärkt BD's Position in intelligenten, vernetzten Pflegetechnologien.
- First-to-market Cerebral Autoregulation Index (CAI) technology provides competitive advantage
- Clinical validation through multicenter studies demonstrates product effectiveness
- Expansion into advanced patient monitoring market through strategic acquisition
- Enhanced user interface and workflow efficiency features may drive adoption
- Significant R&D investment required for AI-driven technology development
- Complex implementation may require additional training and support resources
- Competition in medical device monitoring space could impact market share
Insights
BD's new AI-powered hemodynamic platform introduces predictive algorithms for blood pressure management, advancing critical care monitoring technology.
BD's launch of the HemoSphere Alta™ platform represents a significant advancement in hemodynamic monitoring technology, featuring AI-driven algorithms that help clinicians predict and address blood pressure instability during procedures. This is the first major product from the Advanced Patient Monitoring business since its acquisition by BD.
The platform introduces the Cerebral Autoregulation Index (CAI), a first-of-its-kind parameter that indicates whether a patient's brain is maintaining stable blood flow despite blood pressure fluctuations. This requires the combination of a noninvasive ForeSight IQ™ Sensor on the patient's forehead and an Acumen IQ™ Sensor connected to the arterial line.
Another key feature is the Acumen Hypotension Prediction Index (HPI)™ software, which predicts low blood pressure events before they occur. According to the article, this technology has been "demonstrated to reduce the depth, duration and severity of hypotension in several large multicenter studies."
The hardware design includes a 15-inch high-resolution touchscreen with customizable displays and split-screen views. Voice and gesture command features enable hands-free interaction while maintaining sterility in clinical environments.
This product strengthens BD's portfolio of smart, connected care technologies that leverage clinical data and AI for improved decision support in critical care settings.
New hemodynamic monitoring system offers personalized blood pressure thresholds and predictive algorithms, potentially transforming proactive patient care.
The HemoSphere Alta™ platform introduces clinically significant innovations that address critical challenges in hemodynamic monitoring. The integration of predictive algorithms represents a paradigm shift from reactive to proactive management of hemodynamic instability in critical care.
The Cerebral Autoregulation Index addresses an important clinical challenge: the significant patient-to-patient variability in optimal blood pressure parameters. As Dr. Hogue notes, research has demonstrated "wide variability of the lower limit of cerebral blood flow autoregulation between individuals" and increased risks when pressure falls below patient-specific thresholds. This technology could help clinicians detect "conditions of impaired autoregulation" and identify individual lower limits.
By combining this with the Hypotension Prediction Index, which has multicenter study validation, clinicians can both identify patient-specific thresholds and receive advance warning of hypotensive episodes, enabling earlier intervention.
The platform's improved user interface with voice and gesture controls addresses practical challenges in sterile environments. The larger 15" customizable display with minimized pop-ups shows thoughtful design based on clinical workflow needs.
This technology represents a meaningful advance in critical care monitoring by providing both predictive capabilities and personalized insights, potentially improving clinical decision-making in situations where precise hemodynamic management impacts patient outcomes.
HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations
HemoSphere Alta™ platform is the company's most advanced hemodynamic monitoring technology available and is the first major product launch from the Advanced Patient Monitoring business since its acquisition by BD. The new product advances BD's leadership in smart, connected care technologies that use clinical data and AI to help clinicians improve patient outcomes and optimize clinical workflows.
One of the key innovations is the new Cerebral Autoregulation Index (CAI), a first-of-its-kind parameter that indicates whether the brain is likely to maintain stable blood flow despite changes in blood pressure and offers personalized insights into a patient's blood pressure requirements. Clinicians can access CAI when using a noninvasive ForeSight IQ™ Sensor, placed on the patient's forehead, combined with an Acumen IQ ™ Sensor, connected to the patient's arterial line. The HemoSphere Alta™ platform also includes the Acumen Hypotension Prediction Index (HPI)™ software that predicts when a patient could have a low blood pressure event, which has been demonstrated to reduce the depth, duration and severity of hypotension in several large multicenter studies.
"Research over the past two decades has demonstrated the wide variability of the lower limit of cerebral blood flow autoregulation between individuals, as well as the risk for patient morbidity and mortality when blood pressure is maintained below this threshold," said Dr. Charles Hogue, chairman of the Department of Anesthesiology at Northwestern University Feinberg School of Medicine in
The new monitor also features an improved design to streamline the user experience, including a larger 15" high-resolution, customizable touchscreen display, split-screen views and is designed to minimize disruptive pop-ups. Voice and gesture command features help maintain sterility and allow for hands-free interaction with the monitor, such as silencing alarms and switching views. These improvements offer a more intuitive and efficient interface.
"HemoSphere Alta™ marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability," said Tim Patz, president of BD Advanced Patient Monitoring. "These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients."
With the recent acquisition of Advanced Patient Monitoring, BD continues to advance its collaboration with clinicians to develop advanced patient monitoring solutions that help improve the quality of care for patients around the world. For more information about HemoSphere Alta™, visit bd.com/HemoSphereAlta.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-launches-next-generation-hemodynamic-monitoring-solution-providing-clinicians-with-ai-driven-clinical-decision-support-302433318.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What are the key features of BD's new HemoSphere Alta monitoring platform?
How does the Cerebral Autoregulation Index (CAI) in BDX's HemoSphere Alta work?
What clinical benefits does BD's Acumen Hypotension Prediction Index offer?
How does BDX's HemoSphere Alta improve workflow efficiency for clinicians?
